+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost-effectiveness of tumor necrosis factor-alpha antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis



Cost-effectiveness of tumor necrosis factor-alpha antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis



Expert Review of Pharmacoeconomics and Outcomes Research 7(2): 155-169



The treatment of chronic arthritic diseases has undergone some dramatic changes over the past few years. In particular, a new class of drugs called the tumor necrosis factor-alpha antagonists has transformed the management of rheumatoid arthritis, and decision makers are now consid1ering their use in psoriatic arthritis and ankylosing spondylitis. Whilst short-term clinical trials suggest that tumor necrosis factor-alpha antagonists improve physical function and pain linked to disease activity, this class of drug has generated controversy owing to its substantial cost. Pharmacoeconomic studies conclude that tumor necrosis factor-alpha antagonists result in significant increases in health-related quality of life; however, the cost-effectiveness of this class of drug remains uncertain, particularly in the treatment of psoriatic arthritis and ankylosing spondylitis. This paper reviews pharmacoeconomic analyses examining the cost-effectiveness of tumor necrosis factor-alpha inhibitors in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052371290

Download citation: RISBibTeXText

PMID: 20528442

DOI: 10.1586/14737167.7.2.155


Related references

Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. Journal of Rheumatology 36(7): 1421-1428, 2009

The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis and Rheumatism 59(2): 234-240, 2008

Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures?. Arthritis and Rheumatism 61(6): 801-812, 2009

Methodological concerns in tumor necrosis factor (TNF) inhibitor trials in rheumatoid arthritis (RA), psoriatic arthritis (PSA) and ankylosing spondylitis (AS): power calculations and 1 versus 2-tailed statistical tests. 2007

AB1120Comparison of Long-Term Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis: A Single Center Turkish Experience Over a Decade. Annals of the Rheumatic Diseases 74(Suppl 2): 1275.2-1276, 2015

Effectiveness and safety of adalimumab (humiha) therapy after failure of prior TNF-antagonists in patients with rheumatoid arthritis (RA), psoriatic arthritis (PSA), and ankylosing spondylitis (AS). 2007

Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis and Rheumatism 64(7): 2068-2077, 2012

FRI0353Association of Attitudes Toward Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs and Tumor Necrosis Factor Inhibitors and Treatment Adherence in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: Results from the Global Align Study:. Annals of the Rheumatic Diseases 74(Suppl 2): 553.2-554, 2015

Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Annals of the Rheumatic Diseases 66(10): 1393-1397, 2007

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Research and Therapy 12(3): R117, 2010

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. Journal of Rheumatology 35(9): 1745-1753, 2008

Association of single nucleotide polymorphism at position -308 of the tumor necrosis factor-alpha gene with ankylosing spondylitis and rheumatoid arthritis. Biotechnology Biotechnological Equipment 28(6): 1108-1114, 2014

Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Annals of the Rheumatic Diseases 65(9): 1175-1183, 2006

Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Review of Clinical Immunology 6(5): 721-733, 2010

Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study. Joint Bone Spine 83(5): 607-609, 2016